Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

Q&A med Zealand Pharma, 3 December kl 16.00 Læs mere her
      
side 1 / 258
Opret nyt indlæg

Det ligner en and, så er det sgu nok en and.
13/11 10:31 Helge Larsen/PI-redaktør Svar: 4

Rumrejser - Wall Street's nye trillion-doll..
13/11 08:33 Helge Larsen/PI-redaktør Svar: 1

Ta Novo n
12/11 21:04 Jeos Svar: 2

regnskab
12/11 21:00 nocash Svar: 4

DLH
12/11 20:59 Match Svar: 5

sas.co
12/11 13:33 Aftenbakken Svar: 3

Tvivl om Whistleblower
12/11 08:22 Jensen100 Svar: 4

Korte netto-positioner ultimo oktober
11/11 23:35 tommycarstensen Svar: 2

Orphazyme - hvem er inde i casen?
11/11 17:19 BurnMe Svar: 1

Torm
11/11 16:34 Esset Svar: 5

CO2 Combat 14 Internet of Things #1- with L..
11/11 12:02 Helge Larsen/PI-redaktør Svar: 0

Forskellig kurs
11/11 09:40 Lasse Drescher Svar: 0

$SOGO En video om Sogou, Baidus største kon..
10/11 21:33 Mads Christiansen Svar: 1

GENMAB Præsentationer
10/11 20:11 peter12 Svar: 1

Mulighed for at tegne aktier i Braincool
10/11 13:30 henningoslo Svar: 8

Danske Bank tilbød guld .........
10/11 13:20 Kokdenrigtige Svar: 2

MICROCRAP FRAUD - SÅDAN SER DU FARESIGNALER..
9/11 21:28 Helge Larsen/PI-redaktør Svar: 0

LAKSEPRISEN ER I JULEHUMØR
9/11 20:01 Helge Larsen/PI-redaktør Svar: 10

Gearede produkter
9/11 19:35 Aliaz Svar: 2

Veloxis
9/11 13:52 Kevinstein Svar: 1

Veloxis
9/11 13:46 Kevinstein Svar: 0

Veloxis test
9/11 13:43 Kevinstein Svar: 0

THORIUM 232 - From History to Reactor
9/11 13:23 Helge Larsen/PI-redaktør Svar: 5

Hjælp....
9/11 11:59 Kevinstein Svar: 3

Genmab´s HexaBody® technology
9/11 11:16 Helge Larsen/PI-redaktør Svar: 1

LIVE-SESSION MED GENMAB D. 8. NOV. 2019
8/11 22:49 Helge Larsen/PI-redaktør Svar: 1

Er markedet blevet for grådigt?
8/11 13:26 Markettimer Svar: 12

SAS - opjustering og fest!
8/11 12:55 Arne A Svar: 2

"Kop med begyndende håndtag" i Genmab.
8/11 11:50 Helge Larsen/PI-redaktør Svar: 12

Rovsing - den glemte aktie
8/11 11:05 Match Svar: 2

Fingerprint
8/11 09:39 TheNote Svar: 13

VESTAS: Offshore wind set to become $1 tril..
8/11 08:43 Helge Larsen/PI-redaktør Svar: 0

Iss
8/11 08:18 Jensen100 Svar: 2

Ørsted hvem skal man tro på.rbc cipital ell..
7/11 18:40 christian1909 Svar: 0

Danske Bank: lav kurs udfordrer tålmodige i..
7/11 17:52 Helge Larsen/PI-redaktør Svar: 5

Bitcoin & Bentleys i cryptovalley med Nikla..
7/11 17:30 Marthine/PI-Redaktør Svar: 3

Markedet generelt
7/11 13:09 Læreren Svar: 4

ISS nedtur
7/11 11:11 DjengisCash Svar: 19

STG - ved at bryde nedtrenden
7/11 11:07 Kongkurs Svar: 4

VESTAS Q3 REGNSKAB
7/11 08:28 Helge Larsen/PI-redaktør Svar: 7

Transcript of GEN.CO earnings conference ca..
7/11 08:18 Helge Larsen/PI-redaktør Svar: 0

vestas
7/11 08:00 børshaj Svar: 4

TEVA: Teva: Kulminerede aktiefrygten i okto..
7/11 07:35 Helge Larsen/PI-redaktør Svar: 15

GRIEG SEAFOOD - Q3
7/11 06:36 Helge Larsen/PI-redaktør Svar: 0

ONCOLOGY VENTURE- Q&A D.6/11-2019 - TRANSCR..
6/11 22:52 Helge Larsen/PI-redaktør Svar: 2

Donation
6/11 18:36 Luckyluke Svar: 1

NorthMedia
6/11 16:30 Match Svar: 3

Er løbet kørt for disse 4 aktier?
6/11 14:15 Markettimer Svar: 3

Regnskab
6/11 12:15 Roadrunner Svar: 15

Veloxis
6/11 12:08 børshaj Svar: 4


Genmab´s HexaBody® technology

  


The HexaBody® technology is Genmab's proprietary antibody platform which allows for the creation of potent therapeutics by inducing antibody hexamer formation after target binding at the cell surface

The HexaBody technology builds on natural antibody biology and enhances the assembly of antibody hexamers (clusters of six) after target binding at the cell surface. This results in enhancement of immune effector functions including complement-mediated killing (complement-dependent cytotoxicity (CDC)). The HexaBody technology can transform antibodies with limited or absent CDC into potent, cytotoxic antibodies.

The HexaBody® technology builds on novel insights in the natural biology of antibodies

Antibodies play an important role in the activation of the complement system, a part of the innate immune system that is instrumental in the clearance of bacteria and viruses from the body. Antibodies can also be employed in therapy of detrimental diseases such as cancer. The importance of complement in antibody-mediated immunity and their therapeutic efficacy has been known for decades, yet only recently molecular insight was given into the interaction between IgG antibodies and complement.

Upon binding to their target molecules on a cell, antibodies were found to group together in rings of six:hexamers. This process is driven by non-covalent interactions between the Fc domains of adjacent antibodies. The formation of hexamers was found critical for optimal binding of the first component of the complement cascade, C1, which was evaluated by different exploratory techniques. Once this first component is bound, the complement cascade is triggered, eventually leading to formation of a membrane attack complex. This complex forms a hole in the cell membrane, and the cell dies.

By engineering the Fc domains of the antibodies, the hexamer formation may be increased whereby the efficacy of complement-dependent cytotoxicity (CDC) of target cells can be enhanced. This novel insight forms the basis of the HexaBody technology.

http://www.genmab.com/hexabody/Technology#tab1




Current progress in innovative engineered antibodies:

https://link.springer.com/article/10.1007/s13238-017-..


Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody:

https://journals.plos.org/plosbiology/article?id=10.1..




side 1 / 258
Opret nyt indlæg